Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

CMV pp65 mRNA lipid particle vaccine

An off-the-shelf (OTS) lipid particle (LP)-based cancer priming vaccine containing messenger RNA (RNA) encoding the human cytomegalovirus (CMV) matrix protein pp65 (65 kDa lower matrix phosphoprotein; UL83), with potential immunostimulatory and antineoplastic activities. Upon administration of CMV pp65 mRNA LP vaccine, the mRNA is taken up, translated and presented by antigen presenting cells (APCs), mainly dendritic cells (DCs). This may result in a specific cytotoxic T-lymphocyte (CTL) response against CMV pp65-expressing tumor cells leading to tumor cell lysis. The CMV pp65 protein is the primary component of the enveloped subviral particle of CMV and is expressed in certain tumor types.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:CMV pp65 mRNA vaccine
CMV pp65 RNA-loaded lipid particles
CMV pp65 RNA-LPs
pp65 mRNA-loaded LPs
pp65 RNA LP
pp65 RNA LPs
pp65 RNA-LP vaccine
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search